Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| FTKI | 19.40 | 0.08 | +0.42% |
| First Trust Small Cap Buywrite Income ETF | |||
| OCCI | 2.18 | N/A | N/A |
| OFS Credit Company | |||
| VGHY | 71.87 | -0.29 | -0.40% |
| Vanguard High-Yield Active ETF (VGHY) | |||
| FDEC | 56.13 | -0.30 | -0.54% |
| FT Vest US Equity Buffer ETF - December (FDEC) | |||
| TXBC | 16.77 | -0.34 | -2.00% |
| 21Shares FTSE Crypto 10 ex-BTC Index ETF (TXBC) | |||
A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.
| Ticker / NAME | Correlation To BEAM | 1D Price Change % | ||
|---|---|---|---|---|
| BEAM | 100% | -5.10% | ||
| CRSP - BEAM | 77% Closely correlated | -4.41% | ||
| EDIT - BEAM | 66% Closely correlated | -3.69% | ||
| PRME - BEAM | 64% Loosely correlated | -3.88% | ||
| NTLA - BEAM | 59% Loosely correlated | +0.71% | ||
| RXRX - BEAM | 59% Loosely correlated | -16.71% | ||
More | ||||
a company, which develops and commercializes DNA base editing technologies for the treatment of human disease.
Industry Biotechnology
BEAM saw its Momentum Indicator move below the 0 level on October 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 79 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The 50-day moving average for BEAM moved below the 200-day moving average on September 14, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BEAM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for BEAM entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BEAM's RSI Oscillator exited the oversold zone, 23 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for BEAM just turned positive on September 29, 2026. Looking at past instances where BEAM's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.
Following a +5.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where BEAM advanced for three days, in 198 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.345) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (15.314) is also within normal values, averaging (437.542).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. BEAM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BEAM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.